Skip to main content

Table 1 Baseline characteristics of the study population

From: The triglyceride paradox in the mortality of coronary artery disease

Characteristics Total Tertile 1 Tertile 2 Tertile 3 p value
No. of patients n = 3061 n = 1039 n = 1019 n = 1003  
Age, yrs 64.41 (10.68) 66.36 (10.21) 64.55 (10.33) 62.24 (11.09) < 0.001
Gender, men, n (%) 2429 (79.4) 861 (82.9) 790 (77.5) 778 (77.6) 0.003
Medical history
 Pre-hypertension, n (%) 1684 (55.3) 568 (54.9) 581 (57.2) 535 (53.7) 0.270
 Pre-diabetes mellitus, n (%) 665 (21.8) 187 (18.1) 259 (25.5) 219 (22.0) < 0.001
 Pre-myocardial infarction, n (%) 830 (27.1) 303 (29.2) 283 (27.8) 244 (24.3) 0.041
 Pre-PCI, n(%) 365 (11.9) 143 (13.8) 114 (11.2) 108 (10.8) 0.076
 Pre-CABG, n(%) 34 (1.1) 9 (0.9) 13 (1.3) 12 (1.2) 0.642
At admission
 Systolic blood pressure, mm Hg 130.72 (22.33) 129.09 (23.12) 131.21 (22.92) 131.91 (20.76) 0.013
 Diastolic blood pressure, mm Hg 76.49 (12.57) 75.31 (12.76) 76.58 (12.38) 77.62 (12.46) < 0.001
 Heart rate, beats/min 74.34 (22.98) 74.88 (29.59) 74.30 (22.92) 73.82 (13.11) 0.584
 Killip classification ≥ II, n (%) 345 (11.3) 136 (13.1) 121 (11.9) 88 (8.8) 0.007
 GRACE score 92.74 (26.00) 96.44 (25.92) 93.32 (25.94) 88.30 (25.49) < 0.001
 BMI 24.40 (6.75) 23.55 (3.34) 24.72 (10.34) 24.94 (4.23) < 0.001
Laboratory values
 Serum creatinine, μmol/L 93.90 (50.39) 89.46 (30.49) 96.19 (57.84) 96.19 (58.01) 0.002
 Blood glucose, mmol/L 6.95 (3.13) 6.57 (2.75) 7.09 (3.27) 7.20 (3.294) < 0.001
 Total cholesterol, mmol/L 4.07 (1.12) 3.69 (0.94) 4.02 (1.00) 4.52 (1.25) < 0.001
 TG, mmol/L 1.75 (1.13) 0.91 (0.18) 1.48 (0.19) 2.89 (1.32) < 0.001
 LDL, mmol/L 2.46 (3.48) 2.14 (0.80) 2.41 (0.89) 2.83 (5.95) < 0.001
 HDL, mmol/L 1.15 (0.35) 1.26 (0.34) 1.15 (0.36) 1.03 (0.31) < 0.001
 Hemoglobin, g/L 134.39 (31.12) 131.54 (16.76) 133.48 (18.05) 138.28 (48.10) < 0.001
 White blood cell, n×109/L 7.48 (4.94) 7.13 (3.00) 7.69 (7.06) 7.64 (3.78) 0.017
Severity of CAD
 Left main artery, n (%) 284 (9.3) 95 (9.1) 102 (10.0) 87 (8.7) 0.575
 Three vessel diseases, n (%) 795 (26.0) 246 (23.7) 280 (27.5) 269 (26.8) 0.109
 No. of stents 1.22 (1.22) 1.17 (1.19) 1.26 (1.21) 1.24 (1.27) 0.195
Diagnose
 ACS, n(%) 2174 (71.0) 715 (68.8) 715 (70.2) 744 (74.2) 0.022
 AMI, n(%) 636 (20.8) 219 (21.1) 213 (20.9) 204 (20.3) 0.912
Discharge medications
 Aspirin, n (%) 2812 (91.9) 951 (91.5) 938 (92.1) 923 (92.0) 0.963
 Clopidogrel, n (%) 2735 (89.3) 905 (87.1) 917 (90.0) 913 (91.0) 0.088
 Statins, n (%) 2754 (90.0) 934 (89.9) 921 (90.4) 899 (89.6) 0.958
 ACE inhibitors or ARBs, n (%) 1753 (57.3) 601 (57.8) 572 (56.1) 580 (57.8) 0.950
 Beta-receptor blockers, n (%) 2028 (66.3) 634 (61.0) 671 (65.8) 723 (72.1) < 0.001
  1. Data are expressed as means ± SD or counts and percentages, as appropriate
  2. Abbreviations: BMI body mass index, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, TG triglyceride, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, CAD coronary artery disease, ACE angiotensin-converting enzyme, ARBs angiotensin-receptor blockers, GRACE score Global Registry of Acute Coronary Events score